1.05
Schlusskurs vom Vortag:
$1.055
Offen:
$1.09
24-Stunden-Volumen:
87,574
Relative Volume:
0.56
Marktkapitalisierung:
$15.42M
Einnahmen:
$500.00K
Nettoeinkommen (Verlust:
$-19.45M
KGV:
-0.5556
EPS:
-1.89
Netto-Cashflow:
$-18.22M
1W Leistung:
+0.96%
1M Leistung:
+17.88%
6M Leistung:
+5.02%
1J Leistung:
-40.00%
Imunon Inc Stock (IMNN) Company Profile
Firmenname
Imunon Inc
Sektor
Branche
Telefon
(609) 896-9100
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Vergleichen Sie IMNN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IMNN
Imunon Inc
|
1.05 | 15.42M | 500.00K | -19.45M | -18.22M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Aktie (IMNN) Neueste Nachrichten
DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks
Stacy Lindborg, PhD's Profile Page - Technology Networks
Companies To Watch: Imunon - Life Science Leader
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research
Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo
Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World
IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks
IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire
Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan
IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com
Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks
Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com
Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance
IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks
Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com
Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView
IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView
IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire
IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance
Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks
IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan
Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily
The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times
IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com
Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan
IMUNON names Douglas Faller as chief medical officer - MSN
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Imunon names industry vet Douglas Faller as CMO - The Pharma Letter
Imunon Appoints Dr. Douglas Faller as CMO - TipRanks
Oncology Veteran Takes Helm at IMUNON as Phase 3 Trial ApproachesKey Details - Stock Titan
Imunon director Donald Braun acquires $29,480 worth of shares - MSN
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Biotech's Target Price 183.757% Higher Than Current - Streetwise Reports
Is Rigetti Computing Stock a Buy in 2025? - The Globe and Mail
Finanzdaten der Imunon Inc-Aktie (IMNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):